Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion

Cutaneous squamous cell carcinoma (CSCC) is the second most common skin malignancy in white-skinned populations. Only a minority of patients (<5%) develop advanced disease, but this is often difficult to treat and characterised by a poor prognosis. Cemiplimab, a fully human IgG4 monoclonal antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Argenziano, Giuseppe, Fargnoli, Maria Concetta, Fantini, Fabrizio, Gattoni, Massimo, Gualdi, Giulio, Pastore, Francesco, Pellacani, Giovanni, Quaglino, Pietro, Queirolo, Paola, Troiani, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753075/
https://www.ncbi.nlm.nih.gov/pubmed/35035534
http://dx.doi.org/10.1177/17588359211066272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753075/
https://www.ncbi.nlm.nih.gov/pubmed/35035534
http://dx.doi.org/10.1177/17588359211066272

Ejemplares similares